Veracyte | VCYT - Assets


Veracyte reported $1.49B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agenus USD 186.46M 40.34M Mar/2026
Agilent USD 13.07B 252M Mar/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Bruker USD 6.05B 77.8M Jun/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Illumina USD 6.65B 91M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Laboratory Of America USD 18.53B 554.8M Jun/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Siemens EUR 167.54B 428M Jun/2026
Sonic Healthcare AUD 15.38B 550.57M Dec/2024
Thermo Fisher Scientific USD 113.17B 107M Jun/2026
Veracyte USD 1.49B 49.97M Jun/2026
Waters USD 24.75B 220M Jun/2026